AP2a and p53 form nuclear complexes that establish a functional partnership, which regulates the expression of certain genes involved in cell growth and metastasis. The growth effects of AP2a are mediated through p21 WAF1/CIP1 and the ability for AP2a to coactivate p21 requires p53. Herein, we have localized the AP2-binding region of p53 to amino acids 305-375. Analysis of 26 distinct p53 alleles established a correlation between AP2a binding and transcriptional coactivation. The L350P point mutation was the only nonbinding allele that retained normal transcriptional activity by reporter assay. Although both wild-type and L350P alleles facilitated binding of AP2a to the p21 promoter, the L350P allele was significantly reduced in its ability to induce the endogenous p21 gene, demonstrating a striking difference in activity comparing reporter assays with activation of endogenous p53 target genes. Interestingly, expression of AP2 in the absence of radiation repressed p53-mediated induction of p21 and this effect was explained by a reduction in p53 stability induced by AP2a overexpression. We conclude that AP2a has competing effects on p53 activity through coactivation and decreased stability. These findings may provide a mechanism to account for the discrepancies reported for the association between AP2 and p21 expression in tumor tissue.
Introduction
Five members of the AP2 transcription factor family have been identified -AP2a, AP2b, AP2g, AP2d and AP2e (Williams et al., 1988; Moser et al., 1995; Bosher et al., 1996; Zhao et al., 2001; Feng and Williams, 2003) . The AP2 factors are developmentally regulated, retinoic acid-inducible genes that orchestrate a variety of cell processes including apoptosis, cell growth and tissue differentiation during embryogenesis (Zhang et al., 1996; Moser et al., 1997) . Studies in mice have indicated an important role of AP2 factors in the development of neural crest, epidermal, placental and urogenital tissues (Zhang et al., 1996; Moser et al., 1997; Nottoli et al., 1998; West-Mays et al., 1999; Hilger-Eversheim et al., 2000) . Early in embryogenesis, AP2a null/null mice have failure of cranial neural-tube closure and defects in cranial ganglia development (Zhang et al., 1996) . Later in embryogenesis, the mice develop craniofacial defects and thoraco-abdominoschisis with deformed or absent skeletal bones. A variety of ocular phenotypes have also been described including anophthalmia or abnormal lens morphogenesis (Nottoli et al., 1998; West-Mays et al., 1999) . The AP2b null/null mouse phenotype is associated with normal glomerular and tubular differentiation, but at the end of embryonic development, the mice develop massive apoptotic death of the collecting duct and distal tubular epithelia (Moser et al., 1997) . AP2g is expressed in the extra-embryonic membranes and is required for the normal development of this compartment and also for survival of the mouse embryo (Auman et al., 2002) .
The AP2 family members regulate the expression of a variety of genes in differentiated tissues and tumor cells. There may also be differences in functional activity of different family members. However, studies that have directly compared the DNA-binding specificity and transcriptional activation of heterologous promoters have failed to detect significant differences (McPherson and Weigel, 1999) . AP2 factors regulate the expression of genes in various tissues of ectodermal origin. In melanoma cells, AP2 induces the MUC18 and c-KIT promoters (Bar-Eli, 2001 ). Within neuronal tissues, AP2 factors regulate the promoters of tyrosine hydroxylase and dopamine b-hydroxylase through multiple and single AP2-binding sites, respectively (Kim et al., 2001) . In breast cancer, the AP2 factors have been implicated in the overexpression of the ErbB2 (Bosher et al., 1995; Bosher et al., 1996) and ERa genes (deConinck et al., 1995; McPherson et al., 1997) . In hepatoblastoma and colon carcinoma cell lines, AP2 induces the expression of p21 WAF1/CIP1 , which has been thought to be the basis for the ability of AP2 to control cell growth (Zeng et al., 1997) .
There are several examples in which AP2 factors act cooperatively with other nuclear factors to regulate the expression of promoters through tandem or closely associated regulatory elements. AP2 and p53 act synergistically to induce expression of the gelatinase A (matrix metalloproteinase 2) gene promoter (Mertens et al., 2002) and the KAI1 gene promoter (Marreiros et al., 2005) . In hepatocytes, AP2 factors act in a coordinate fashion with NF-kB to regulate the cholecystokinin promoter (Katsel and Greenstein, 2001 ) and the serum amyloid A1 (SAA) promoter (Ren and Liao, 2001) . AP2 has been reported to act synergistically with retinoic acid receptors to activate the CRABPII (Astrom et al., 1992; Oulad-Abdelghani et al., 1996) and the HOX A4 gene promoters (Doerksen et al., 1996) . There is evidence that AP2 is able to repress expression of several promoters including SAA, a-fetoprotein, albumin and hepatocyte growth factor through competition with overlapping binding sites of other trans-activators (Jiang et al., 2000; Ren and Liao, 2001) .
In addition to the coordinate regulation based on tandem regulatory elements, AP2 factors establish a cooperative partnership with other transcription factors through a mechanism that depends upon a direct proteinprotein interaction. Interactions between AP2 factors and Rb have been reported to be important for regulation of the E-cadherin gene in epithelial cells (Batsche et al., 1998) . Based on GST pulldown and co-immunoprecipitation, AP2 factors have been demonstrated to bind to p53 in vitro and in vivo (McPherson et al., 2002; Modugno et al., 2002) . Using a p53-responsive reporter assay, AP2a coactivated p53-mediated transcription and appeared to act through the p53 regulatory element (McPherson et al., 2002) . AP2a was demonstrated to target the p21
gene promoter in the region of the p53 regulatory region only in the presence of p53 and the ability of AP2a to induce endogenous p21 WAF1/CIP1 was dependent upon p53 expression (McPherson et al., 2002; Wajapeyee and Somasundaram, 2003) . Furthermore, the ability of AP2a to induce G1 and G2 cell cycle arrest (McPherson et al., 2002) and inhibit cell growth (Wajapeyee and Somasundaram, 2003) in HCT116 cells required the presence of p53. Interestingly, the interaction between AP2 and p53 can repress AP2 activity as demonstrated by repression of AP2-mediated induction of the laminin receptor gene by p53 overexpression (Modugno et al., 2002) .
Important questions remain concerning the mechanisms through which AP2 and p53 establish a functional partnership. In the current study, we sought to characterize the interaction between AP2a and p53 by defining the AP2-interaction domain of p53. By developing point mutations of p53 with altered AP2 binding, we addressed to what extent the physical interaction of AP2a and p53 is required for AP2-mediated coactivation of p53 transcription. We have also investigated additional mechanisms through which the interaction of AP2a and p53 regulate the expression of endogenous p21 WAF1/CIP1 .
Results

Identification of the p53 domain that interacts with AP2a
We were interested in examining how mutations of p53 affect the interaction between p53 and AP2a. In so doing, we also expected to define the region of p53 that interacts with AP2a. Using RT-PCR, we cloned 25 distinct p53 cDNAs, which were derived from cell lines and breast tumors. A schematic representation of each point mutation is shown in Figure 1 . Each mutated p53 protein was tested for binding to AP2a by GST pulldown and the binding affinity was compared to that for wild-type (WT) p53. Seven of the p53 mutants (mutation numbers: M1, M3, M13, M14, M15, M17 and M22) demonstrated binding affinity that was less than 10% of the binding affinity compared to WT p53. Five of these mutations were missense mutations and two were the result of abnormal splicing that creates a frame shift after amino acid 331. As shown in Figure 1 , all seven of the nonbinding mutations have a deletion or mutation within or near the tetramerization domain, which includes residues 325-355 (Brokx et al., 2003) . Also evident from the data is that numerous missense mutations located throughout other regions of the p53 protein failed to have a significant effect on binding.
To further substantiate the location of AP2a binding, we expressed various regions of p53 with particular interest focused on the tetramerization domain. As seen in Figure 2 , all deletions that involve amino acids 327-351 fail to bind to AP2a. Interestingly, a protein with deletion of amino acids 351-393 retains binding activity, although binding of this mutant appears to be reduced compared to WT p53. The region of p53 from amino acids 305-375 was expressed as a fusion protein with an amino-terminal FLAG tag (F) and a carboxyl-terminal green fluorescent protein (GFP). Including FLAG was done to provide an antigen to examine the protein by Western blot and GFP was included to increase the size of the protein to facilitate resolution by PAGE. As shown in Figure 2 , a chimeric FLAG-green fluorescent protein (F-GFP) does not bind to AP2a. However, when the region of p53 from amino acids 305-375 is included, the chimeric protein F(305-375)GFP demonstrated binding to AP2a. As noted from analysis of mutation M17 in Figure 1 , a p53 protein with the missense mutation L350P does not bind to AP2a. Hence, the L350P point mutation was cloned into the chimeric protein F(305-375)GFP, called F(305-375)350PGFP. As shown in Figure 2, Modugno et al., 2002) . We coexpressed AP2a with either WT p53 or the L350P mutant p53 protein (mutant M17) by transfection into cells that did not express endogenous AP2a or p53 and examined the interaction in vivo by co-immunoprecipitation. As seen in Figure 3a , HCT116 p53À/À cells did not express either p53 or AP2a and demonstrated good expression of either protein after transfection of the appropriate expression vector. We used conditions that gave equal expression of WT and L350P (M17), performed immunoprecipitation with anti-AP2a antibody and analysed p53 by Western blot. Under parallel conditions, the amount of M17 co-immunoprecipitated was reduced to approximately 25% compared to WT p53 (see Figure 3b) . As a negative control, immunoprecipitations performed with an IgG control antibody failed to precipitate p53. These results confirm the in vivo interaction between AP2a and p53. Although an interaction is detected between the mutant p53 protein L350P (M17) and AP2a, the interaction is reduced compared to WT p53. Figure 1 Testing mutations of p53 for AP2a binding. Various mutations of p53 were cloned and expressed by in vitro transcription/ translation. Each protein was tested for binding to AP2a by GST pulldown. At top is a schematic representation of p53 with the functional domains for transactivation (TAD), DNA binding (DNA BD) and tetramerization (TD). In the schematic below are shown the structure of wild-type (WT) and various mutants of p53 with the location of point mutations shown for each mutation. The results of the GST pulldown are shown for each p53 mutant on the left side of the figure. Seven mutations highlighted with a dot (M1, M3, M13, M14, M15, M17 and M22) demonstrated binding to AP2a that was less than 10% compared to WT-p53. Note that p53 alleles that fail to bind to AP2a have a point mutation or deletion involving the region within or near the tetramerization domain (highlighted in gray).
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Correlation of AP2a binding and transcriptional coactivation
We have previously demonstrated that AP2a coactivates p53-mediated transcription from a heterologous p53 reporter (McPherson et al., 2002) . We sought to characterize the ability of AP2a to coactivate transcriptional activity of the various p53 mutants. For these experiments, we used HCT116 cells in which both p53 alleles were deleted (HCT116 p53À/À), thereby eliminating endogenous p53 activity. The cDNAs for the various p53 mutations were cloned into an expression vector and cotransfected with a p53 luciferase reporter either with or without an expression vector for AP2a. As seen in Figure 4a , the p53 mutations were screened for transcriptional activity and coactivation by AP2a. As a first point, the data in Figure 4a corroborate earlier reports demonstrating that AP2a coactivates the transcriptional activity of WT p53. Furthermore, analysis of the data based on WT and 25 mutant p53 proteins (summarized in Table 1 ) reveals several interesting patterns that can be used to generalize the findings. Nine of the 19 p53 proteins that bind AP2a and four of the seven nonbinding proteins lack transcriptional activity, and the expression of AP2a failed to have an Extracts not subjected to immunoprecipitation were analysed by Western blot in parallel (p53 Load). Protein for p53 synthesized by in vitro transcription/translation (TNT) is added as a positive control for the Western blot.
AP2a affects transcription and stability of p53 PR Stabach et al affect on the transcriptional activity of these 13 p53 mutants. These data suggest that coactivation by AP2a requires the presence of a p53 protein with an ability to activate transcription that is comparable to WT p53. Of the 10 alleles that had transcriptional activity comparable to WT p53 and bound to AP2a, all 10 were coactivated by AP2a. Three nonbinding mutants of p53 retained significant transcriptional activity. Mutants M1 and M22 are splice mutants that delete the carboxy terminal 62 amino Figure 4 Transcriptional coactivation correlates with binding to AP2a. The transcriptional activities of the various alleles of p53 were tested for coactivation by AP2a using a p53 luciferase reporter. (a) Screening for coactivation: All p53 alleles were tested for coactivation by AP2a with results shown in duplicate. The normalized relative light units (RLU) are shown without cotransfection of AP2a (À) or with AP2a ( þ ). Nonbinding alleles of p53 are indicated with a dot (). Note that the nonbinding allele M17 has transcriptional activity comparable to WT p53, but is not coactivated by AP2a. (b) Activity of L350P compared to WT p53: the transcriptional activity of the L350P mutation of p53 was examined compared to WT p53. Top panels show Western blots for p53 and AP2a performed on transfected cells in parallel to confirm expression of the transfected proteins. Normalized RLU from four transfections demonstrate that AP2a coactivates WT p53 but has minimal effect on L350P. (c) Percent increase in transactivation induced by AP2a: The percent increase (coactivation) induced by AP2a is shown for cotransfection data from (b). Note significant reduction in coactivation of L350P compared to WT (Po0.0001).
acids. Consistent with previous studies, these mutant p53 proteins retain transcriptional activity, albeit activation is reduced compared to WT p53 (Chene, 2001) . AP2a failed to coactivate transcriptional activity of these deletion mutants and activity was consistently reduced in the presence of AP2a. One of the nonbinding mutations (M17) retained transcriptional activation that was comparable to WT p53. The data demonstrated that AP2a expression failed to coactivate transcription of the nonbinding L350P (M17) mutant p53 allele.
Transcriptional activity of the L350P allele was examined in more detail. HCT116 p53À/À cells were cotransfected with a p53 luciferase reporter and expression vectors for WT or L350P either with or without an expression vector for AP2a. To assess the level of protein expression, Western blots were performed on cells transfected in parallel and reacted with antibodies to p53 and AP2a. As seen in Figure 4b , HCT116 p53À/À cells do not express detectable amounts of endogenous p53 or AP2a and, after transfection, the L350P mutant allele was expressed to levels comparable to WT p53. Whereas AP2a expression augmented the transcriptional activity of WT p53, coactivation of the L350P allele was significantly reduced. As shown in Figure 4c , AP2a increased the transcriptional activity of WT p53 by 172% compared to 38% for L350P (Po0.0001). These data establish a correlation between a physical interaction of AP2a and p53 and coactivation of p53 transcriptional activity by AP2a. The results suggest that, in addition to a basal level of transcriptional activity by p53, the stable interaction between p53 and AP2 is important for enhancing activation of a reporter by p53.
Effects on the endogenous p21 gene We were interested in determining what effect the L350P (M17) p53 allele would have on endogenous p21 expression. In our earlier studies, we used chromatin immunoprecipitation (ChIP) analysis to examine the interaction between AP2a and the endogenous p21 promoter (McPherson et al., 2002) . We optimized for AP2a expression and performed ChIP analysis in which AP2a was cotransfected into HCT116 p53À/À cells with either WT p53 or the L350P (M17) p53 allele. As seen in Figure 5 , the ability for AP2a to target the p21 promoter in the region of the p53-binding site at -2250 required the expression of p53. The findings with WT p53 confirm our earlier results, which showed that AP2a targeted the p21 promoter in HCT116 p53 þ / þ cells but not in HCT116 p53À/À cells. As seen in Figure 5 , the L350P (M17) allele is able to facilitate the interaction between AP2a and the p21 promoter. This finding agrees with co-immunoprecipitation results, which demonstrated an interaction between AP2a and the L530P allele, despite the lower affinity for the mutated allele.
We have previously demonstrated that AP2a coactivated expression of p21 induced by p53 in the presence of radiation (McPherson et al., 2002) . In previous experiments, we compared HCT116 cells with intact p53 alleles vs HCT116 cells in which the p53 alleles had been disrupted. In the current experiments, we used quantitative RT-PCR (qRT-PCR) to examine the ability of the M17 mutant allele to induce expression of the endogenous p21 gene compared to WT p53. These experiments were performed in HCT116 p53À/À cells, which were cotransfected with a GFP expression vector to allow cell sorting and analysis only of cells expressing the transfected expression vectors. These experiments were also performed without the use of radiation, which had previously been shown to induce p21 expression through stabilization of p53 (Bunz et al., 1998; McPherson et al., 2002) . In the absence of p53, AP2a demonstrated minimal induction of p21 expression (see Figure 6A ). As expected based on previous results, WT p53 induced p21 expression; however, the mutant allele L350P (M17) was significantly reduced in its ability to induce p21 expression. This was particularly surprising since in reporter assays, the M17 allele demonstrated transcriptional activity that was comparable to WT p53 (see Figure 4) . Interestingly, coexpression of AP2a reduced the expression of p21 compared to p53 alone, and the effect of AP2a expression was seen with WT p53 and the M17 mutant p53 allele. However, Western blot analysis performed in parallel revealed that coexpression Figure 5 ChIP analysis of AP2a interaction with p21 promoter.
(a) Schematic of the p21 promoter region with the p53 regulatory region at À2250 and the primers (labeled 'a' and 'b') used for PCR are shown. HCT116 p53À/À cells were cotransfected with expression vectors for AP2a ( þ ) or pCDNA3.1 vector (À) and either wild-type p53 (WT), the L350P p53 allele (L350P) or vector (À). PCR analysis was performed on genomic DNA prior to immunoprecipitation (Genomic) or after immunoprecipitation with anti-AP2a antibody (ChIP). PCR analysis with no template was used as a negative control (+ template).
AP2a affects transcription and stability of p53 PR Stabach et al of AP2a significantly reduced the expression of p53. Hence, the apparent repression of p21 expression by AP2a is likely to be secondary to reduced expression of p53. Although we have shown that overexpression of AP2a can repress p53 expression, we wanted to address whether AP2 expressed at levels normally found in tumor cells is capable of repressing p53 expression and whether a similar effect could be seen with regard to p21 expression. The MCF7 breast carcinoma cell line expresses AP2g and the R72P allele of p53, which is functionally equivalent to WT p53. One advantage of using MCF7 cells is that the only AP2 family member expressed is AP2g (data not shown), which allows the selective knock out of all AP2 activity with the use of siRNA directed against AP2g. As seen in Figure 6b , AP2g siRNA significantly reduced AP2 expression in MCF7 cells and resulted in a twofold increase in p53 expression. Analysis of p21 mRNA demonstrated a 2-3-fold increase in p21 expression associated with the increase in p53 expression. These results indicate that AP2 expression can repress p53 under conditions in which these factors are normally expressed in tumor cells. Furthermore, the expression of AP2 under these conditions can repress p21 expression and this effect can be explained by alterations in p53 levels.
AP2 expression alters p53 stability
The reduced expression of p53 with AP2a coexpression as shown in Figure 6a was also noted to a lesser extent in assays using a luciferase reporter (Figure 4b ). Comparing the two experiments, it is noted that the amount of AP2a expression vector used in the experiments examining the endogenous p21 gene was greater than the amounts used in the experiments using the p53 reporter. Therefore, we examined the effects of increasing amounts of AP2a on expression of p53 under conditions where the total amount of plasmid DNA transfected was held constant by adding empty vector. As shown in Figure 7 , increasing expression of AP2a reduced expression of p53. The expression of endogenous p21 decreased in the lower range of AP2a expression and increased at higher levels of expression. These results indicate that coactivation by AP2a with respect to the regulation of p21 expression by p53 is complex and involves at least two competing mechanisms -one involving a direct transcriptional coactivation of p53 by AP2 and a second competing mechanism in which AP2 reduces the level of p53 expression.
The interaction of p53 with other proteins such as MDM2 is known to alter the stability of p53. We examined whether the half-life of p53 is altered in association with AP2a coexpression. Various concentrations of cycloheximide were examined to optimize conditions to measure the half-life of p53. After 4 h of cycloheximide treatment, there is an obvious difference in the decay of p53 comparing expression of p53 alone with coexpression of AP2a (see Figure 8a) . The half-life of p53 in the absence of AP2a was clearly longer than 4 h, whereas it was estimated to be less than 1 h in the presence of AP2a. A time course using cycloheximide at 100 mg/ml was used to obtain a more accurate determination of the half-life of p53 and demonstrated obvious differences in the decay of p53 either with or without AP2a expression (see Figure 8b and c). In the absence of AP2a, the half-life of p53 was 12.4 h, which is consistent with other reported studies examining p53 half-life under similar conditions (Vega et al., 2004) . By contrast, the half-life of p53 when coexpressed with AP2a was estimated to be 45 min. Hence, there was a 16-fold reduction in the half-life of p53 when AP2a was coexpressed. One could make the argument that earlier time points after cycloheximide are more important. When the data are reanalysed omitting the 24-h time point, the half-life of p53 comparing with or without AP2 expression are still different by an order of magnitude.
Discussion
Studies investigating the patterns of gene expression in primary cancers have reported a loss of AP2a expression with tumor progression in breast cancer (Gee et al., 1999) , colon cancer (Ropponen et al., 2001 ) and melanoma (Karjalainen et al., 1998) . In cell culture models, AP2a has been reported to activate p21
expression resulting in an inhibition of both cell division and stable colony formation (Zeng et al., 1997) . Furthermore, a dominant-negative AP2a mutant has been shown to increase invasiveness and tumorigenicity (Bar-Eli, 1999; Bar-Eli, 2001; Gershenwald et al., 2001) . Overexpression of AP2a in mouse mammary gland using the MMTV promoter suppresses mammary gland growth and development, supporting a role for AP2a in the normal regulation of mammary epithelial cell proliferation (Zhang et al., 2003) . The effects of AP2a on cell growth and its pattern of expression in primary tumors have led to the conclusion that AP2a has tumor suppressor or suppressor-like activity. In some cell lines, it has been hypothesized that the growth suppressive effects of AP2a are mediated through regulation of p21. The role of p21 as a mediator of the biologic function of AP2a is further substantiated by studies demonstrating that the ability of AP2a to inhibit DNA synthesis is lost in p21 null cells (Wajapeyee and Somasundaram, 2003) . Our earlier results demonstrated that the ability of AP2a to induce p21 expression required radiation in the presence of AP2a affects transcription and stability of p53 PR Stabach et al the p53 tumor suppressor gene (McPherson et al., 2002) and subsequent studies using an identical cell system confirmed that induction of p21 by AP2a was significantly more pronounced in the presence of p53 (Wajapeyee and Somasundaram, 2003) . Herein, we show that the effect of AP2a on the expression of p21 is complex and involves p53-dependent and p53-independent mechanisms. In the absence of p53, AP2a has a modest effect on p21 expression. The current data examining the expression of p21 mRNA (as shown in Figure 6a ) is consistent with other published reports, which demonstrated that AP2a has a reduced capacity to induce p21 expression in the absence of p53. Our data using ChIP analysis consistently demonstrated that AP2a does not target the p53 regulatory region of the p21 promoter located at À2250 in the absence of p53. Presumably, AP2a has its effects at other regions of the p21 promoter, potentially involving an AP2-regulatory region identified at -103 (Zeng et al., 1997) . In a recent study involving the KAI1 gene promoter, AP2 and p53 were cooperatively involved in promoter regulation through tandem regulatory elements (Marreiros et al., 2005) . Although AP2 factors clearly induced expression from the KAI1 promoter, it is particularly noteworthy that AP2 had no effect in constructs with a mutated p53 site. The findings with regard to the KAI1 promoter provide additional support for a transcriptional partnership between AP2 and p53 and tend to support a model in which the activity of AP2 at certain promoters is dependent upon the presence of functional p53.
AP2a forms a stable complex with p53 as demonstrated in vitro by GST pulldown and in vivo by co-immunoprecipitation. The data herein have localized the AP2 interaction domain to residues 305-375 and a weaker interaction that includes residues 305-351. The AP2 interaction region includes the tetramerization domain of p53 previously defined by residues 325-355 (Brokx et al., 2003) . Some p53 point mutations that alter binding to AP2a, such as L350P (M17), are likely to disrupt the ability for p53 to form a tetrameric structure. However, the L350P mutation retains a degree of binding to AP2a as noted by co-immunoprecipitation, which is reduced compared to WT p53. This would argue that tetramerization of p53 is not required for an interaction with AP2a, but may help to stabilize the AP2-p53 complex. Furthermore, the region of p53 from 305-375, which contains the direct AP2 interaction domain, includes residues that are targets of phosphorylation and acetylation. Amino acids K305 and K320 are residues known to be acetylation sites (Terui et al., 2003; Wang et al., 2003) and S315 is a target of phosphorylation (Xu, 2003) . It will be interesting to determine if acetylation or phosphorylation of p53 alters the interaction with AP2 factors.
Based on the current data, several models may be considered that could provide a framework for understanding the transcriptional partnership between AP2 and p53. Using the p21 promoter as a model gene promoter, p53 induces transcription by binding to a regulatory element at À2250 and transmitting a signal to the basal transcriptional complex as schematically shown in Figure 9 . In model I, AP2 is proposed to interact at the p53 regulatory site through a direct interaction with p53. Model I is attractive to explain the data in which AP2 coactivates p53-mediated transcription from the p53 reporter since there is no AP2 regulatory region to allow AP2 to bind directly to DNA and mutant p53 proteins that lack AP2 binding (e.g. M17) are not coactivated by AP2. Model II proposes that p53 interaction with its regulatory region induces chromatin alterations that allow AP2 to interact with an AP2 consensus site. This model could apply to either the p21 or KAI1 gene promoters, which are known to have p53 and AP2 consensus binding sites. This model could account for the findings that upregulation of p21 or KAI1 promoters by AP2 requires functional p53, but does not depend upon a direct interaction between AP2 and p53. Model III is a combination of models I and II and indicates that AP2 interaction with its regulatory region and with p53 is needed for signal transduction to the basal transcriptional complex. The complexity of model III offers a possible explanation for the finding that M17, which is deficient in AP2 binding, allows AP2 to bind to the p21 promoter but lacks evidence of transcriptional coactivation. The conclusions that can be drawn in this regard are limited by the biologic fact Figure 9 Models for AP2 coactivation of p53-mediated transcription. Top: schematic of the p21 gene promoter showing p53 binding to its regulatory region at À2250 and transmitting a signal to the basal transcriptional complex (BTC) located at transcriptional start sit. I: Model I proposes that interaction between p53 and AP2 allows association of AP2 with the promoter resulting in increased signal to BTC. II: Model II proposes that the p53 binding to its regulatory site induces chromatin changes allowing AP2 to bind to its regulatory site, thus augmenting transcriptional signaling to BTC. III: Model III shows that binding of factors to their respective sites and the interaction between AP2 and p53 is needed to transmit full transcriptional signal to BTC.
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PR Stabach et al that point mutants such as M17 lack WT transcriptional activity with regard to induction of p21 and have some AP2-binding affinity, albeit reduced compared to WT p53. Hence, the M17 point mutation, which alters AP2a binding, also affects transcriptional activation of the p21 gene promoter making it difficult to assess the independent affects of AP2 binding and transcriptional activity with respect to endogenous gene activation. The models shown in Figure 9 will serve as a useful framework in which to investigate additional mechanisms involving the transcriptional partnership between AP2 and p53. Another interesting finding was that coexpression of AP2a actually reduced the ability for p53 to activate p21 expression and this effect was seen with both WT and L350P p53 alleles. However, overexpression of AP2a resulted in a dose-dependent reduction in p53 expression. Several lines of evidence support the conclusion that overexpression of AP2a decreased the stability of p53. First, cotransfection of AP2a consistently reduced expression of p53. This effect was unlikely to be due to competition of protein expression from plasmids since transfection of an equal amount of vector did not alter p53 expression. In addition, knock down of AP2g expression in MCF7 cells increased endogenous p53 and p21 expression, supporting the findings from experiments in which AP2 was overexpressed. Furthermore, an identical result was seen for endogenous p53 expression when AP2a was overexpressed by adenoviral delivery (See Figure 8 of Wajapeyee and Somasundaram, 2003) . Finally, we measured the stability of p53 with or without overexpression of AP2a (in the absence of radiation) and found a 16-fold difference in the half-life of p53 when AP2a was coexpressed. In our earlier results, overexpression of AP2a in the presence of p53 and radiation induced p21 expression. Since radiation is known to stabilize p53, we conclude that the overall effect of AP2 on the activity of p53 is the result of competing mechanisms -one of which coactivates p53-mediated transcription and the other reduces the level of p53 expression, by altering the stability of p53. It is a common finding that proteins that bind to p53 also alter its stability (Haupt et al., 1997; Kubbutat et al., 1997; Buschmann et al., 2001; Leung et al., 2002; Wulf et al., 2002) . Mdm2 binds to p53, thereby altering its transcriptional activity and targets it for degradation by the ubiquitination pathway. Although AP2a binds in a different region of p53 than Mdm2, it will be interesting to determine if AP2a is also capable of inducing ubiquitination of p53.
Although it has been generally accepted that AP2a induces p21 expression, we have shown that under some conditions AP2 factors can reduce expression of p21. The overall effect of AP2a appears to depend upon the level of AP2a expression, the expression of p53 and possibly the specific allele of p53 expressed. Our findings are particularly relevant when one considers previous studies that have examined p21 and AP2a expression in tumor tissue. Some investigators have reported a positive association between p21 and AP2a expression in colorectal cancer (Ropponen et al., 1999) , breast cancer (Gee et al., 1999) and stage I melanoma (Karjalainen et al., 1998) . By contrast, some studies have reported a negative association between p21 and AP2a expression in prostate cancer (Lipponen et al., 2000) and late-stage melanoma (Baldi et al., 2001) , whereas other investigators have failed to find any correlation between p21 and AP2a expression in ovarian (Anttila et al., 2000) or breast cancer (Pellikainen et al., 2003) . Our conclusion is that the role of AP2a in the regulation of p21 is complex and is likely to vary with the particular cell type, the level of AP2 expression and the activity of p53. Hence, our findings provide an important biologic context in which to understand the association in the expression patterns for AP2a and p21 in studies of primary cancers.
Materials and methods
Cell lines
Cell lines were obtained from ATCC and maintained as previously described (McPherson and Weigel, 1999) . In some experiments, cycloheximide (Sigma-Aldrich, St Louis) was added at the concentration indicated.
Cloning p53 alleles
The p53 alleles were obtained by RT-PCR using RNA isolated from cell lines (MCF7, HBL-100, HeLa, T47D, SW480, MDA-MB-231, HepG2) or from breast tumor tissue. The p53 alleles were cloned by RT-PCR using the primers 5 0 -CAC CATGCTTTGGAAATTGACGGAT and 5 0 -CTTTCTGTG CTTCTCCTCTTTG. All PCR products were cloned into the vector pCR2.1-TOPO (Invitrogen, Carlsbad, CA, USA) and sequenced on both strands. The p53 deletion mutant D181-337 was synthesized by digesting the p53 expression plasmid with Eco47 III and religating the plasmid. The deletion construct D182-339 was synthesized by amplifying a DNA fragment using PCR with the primers 5 0 -CGGAATTCCCGCCATGG AGGAGCCGCAGTCAGATCC and 5 0 -CAGACCATCGCT ATCTGAGCAG and ligating the PCR products into pCR2.1-TOPO. The construct D327-347 was created by digesting the p53 expression plasmid with SspI and StuI and religating the plasmid. The D327-393 was created by digesting the p53 expression plasmid with SspI and BamHI and religating the plasmid. The D351-393 was created by digesting the p53 expression vector with StuI and BamHI and religating the plasmid. The plasmids for F(305-375)GFP and F(305-375)350PGFP were created by ligating three separate DNA fragments. The region of p53 was generated by PCR amplification using either WT or L350P for template with primers 5 0 -CGGATCCATGAAGCGAGCACTGCCCA AC and 5 0 -CGGAATTCCTGACCCTTTTTGGACTTCA GGTGG, which were digested with EcoRI and BamHI. The green fluorescent protein cDNA was obtained as an EcoRINotI DNA fragment from pEGFP-2N (Clontech, Palo Alto, CA, USA). A plasmid derived from pCDNA3.1 containing a FLAG tag was digested with BamHI and NotI. The plasmid F(319-360)GFP was created in a similar fashion with the p53 insert obtained by PCR amplification using primers 5 0 -CGG ATCCATGAAGAAGAAACCACTGGATG and 5 0 -CGGA ATTCCCCTGGCTCCTTCCCAGC. p53 protein was synthesized by in vitro transcription/translation without radioactivity. The protein was detected by Western blot using the DO-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Western blot and co-immunoprecipitation
Western blots and co-immunoprecipitations were performed using antibodies DO-1 for p53 or SC-8975 (Santa Cruz Biotechnology) for AP2a as previously described (McPherson et al., 2002) .
Transient transcription assay
The p53 reporter PG13PyLUC and the p53 expression plasmid Rc/CMVhp53 were obtained as generous gifts from Dr Bert Vogelstein, Johns Hopkins University (Kern et al., 1992) . The mutant p53 expression vectors were obtained by subcloning each mutant p53 cDNA into pCDNA3.1. The AP2a expression vector AP2a/pcDNA3.1has been previously described (McPherson and Weigel, 1999) . HCT116p53À/À cells (gift from Dr Bert Vogelstein) were plated at 1.5 Â 10 5 /35 mm plate in DMEM þ 10% FCS. Cells were transfected using lipofectamin (Invitrogen) with 500 ng of the p53 reporter plasmid, 33 ng pRL-TK Renilla expression control vector (Promega, Madison, WI, USA), 65 ng of a p53 expression vector and either 500 ng of the AP2a expression vector or an appropriate amount of salmon sperm DNA to make the total DNA equal to 1.1 mg. Cell extracts were harvested at 24 h and assayed as previously described except that Renilla was used to control for transfection efficiency (McPherson and Weigel, 1999) .
ChIP assay
ChIP analysis of p21 promoter was performed as described (McPherson et al., 2002) . Briefly, HCT116 p53À/À cells were transfected using FuGENE 6 reagent (Roche Molecular Biochemicals) with pCDNA3.1-AP2a, p53pRC/CMV or pCDNA3.1 keeping the total amount of transfected DNA constant. Cells were harvested 48 h after transfection. Immunoprecipitation was performed with the anti-AP2a C-18 antibody (Santa Cruz Biotechnology). PCR amplification was performed as previously described (McPherson et al., 2002) .
Quantitative RT-PCR HCT116 p53À/À cells were transfected with 1.14 mg pEGFP-N1, with either 1.5 mg pCDNA3.1 vector (No AP2a) or 1.5 mg pCDNA3.1-AP2a (with AP2a) and 0.36mg of expression vectors for WT p53 (pCDNA3.1-p53) or L350P mutant allele (pCDNA3.1-L350P). After transfection, cells were sorted for GFP fluorescence and RNA was isolated from the GFPpositive cells using the RNeasy Mini protocol (Qiagen, Valencia, CA, USA). cDNA was synthesized using SuperScript III First-Strand Synthesis for RT-PCR (Invitrogen) and Anchored oligo(dT)20 primer (Invitrogen). Assay-on-Demand Gene Expression FAM/MGB Probe, nonprimer limited probes for human p21 (Hs00355782) or human b-actin endogenous control (4333762F) and TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, Foster City, CA, USA) were used to perform quantitative PCR using ABI Prism Model 7700 Sequence Detector. In each qPCR assay, samples were run in triplicate, along with three notemplate controls and a standard curve. Data were analysed using ABI Prism 7700 Sequence Detection System software (Applied Biosystems). MCF7 cells were transfected with siRNA directed against AP2g (Dharmacon, Lafayette, CO, USA) according to the manufacturer's instructions and analysed for protein and RNA expression 3 days after transfection.
Measurement of p53 half-life
The expression of p53 was quantitatively determined by Western blot and normalized by actin abundance. The data were analysed by calculating the natural log of the ratio between the normalized level of p53 and the level of p53 at time zero vs time. A linear fit of the data was determined using least squares (JMPIN software, SAS Institute) and the half-life was calculated numerically.
